Real-world data in a post-pandemic world

Biopharma and healthcare organizations were tapping real-world data to inform their decision-making long before COVID-19 roiled global health. Its value was never in doubt: Using information collected outside controlled clinical environments had always been viewed as a crucial step toward better outcomes, even if such information was often considered secondary to more robust randomized data.